Will Infant Eczema Data Change Arcutis Biotherapeutics Stock NarrativeSimplywall·Nov 14, 2026 at 02:26 PMARQT+2.65%
Arcutis' Zoryve cream reduces itch in infants with atopic dermatitis in trialPUBT·Nov 13, 2026 at 02:01 PMARQT+2.65%
Arcutis Grants 58,500 RSUs, 17,000 Stock Options to Six New EmployeesPUBT·Nov 6, 2026 at 09:00 PMARQT+2.65%
TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35TradingView·Nov 5, 2026 at 08:41 PMARQT+2.65%
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Down on Disappointing EarningsMarket Beat·Nov 5, 2026 at 03:40 PMARQT+2.65%
Arcutis Begins Phase 3 Trial of Zoryve Cream 0.3% for Moderate to Severe Atopic DermatitisPUBT·Nov 5, 2026 at 01:04 PMARQT+2.65%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Nov 5, 2026 at 12:05 PMADMA+3.32%ANVS+9.31%
Arcutis Biotherapeutics EVP, Chief Legal Officer Masaru Matsuda Reports Disposal of $1.41 Million in Common SharesPUBT·Nov 4, 2026 at 11:49 PMARQT+2.65%
Arcutis Biotherapeutics Files Initial Beneficial Ownership Statement for EVP, Chief Commercial Officer Robert LisickiPUBT·Nov 4, 2026 at 11:49 PMARQT+2.65%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Nov 4, 2026 at 09:05 PMADMA+3.32%ARQT+2.65%
Arcutis Biotherapeutics tumbles 13% in after-hours tradingMarket Movers·Nov 4, 2026 at 09:05 PMARQT+2.65%
Learn Why The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following Earnings BeatSimplywall·Oct 31, 2026 at 12:58 PMARQT+2.65%
